Two immune-boosting strategies have independently indicated promise in sepsis clinical trials, after years of failures with anti-inflammatories in this same space. Will it be enough to take sepsis drug development out of 'critical condition'?
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Rights and permissions
About this article
Cite this article
Mullard, A. Sepsis researchers set sights on immunotherapeutic strategies. Nat Rev Drug Discov 17, 381–383 (2018). https://doi.org/10.1038/nrd.2018.87
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd.2018.87